Linagliptin — a novel dipeptidyl peptidase-IV inhibitor

Abstract

The diabetes and its complications is one of the five most frequent causes of deaths in the developed countries. So far applied therapeutic proceedings of type 2 diabetic subjects weren’t truly effective. To the purpose of the improvement the results of the treatment one should intensify current therapeutic proceedings or/and enter new groups of drugs into the treatment. One of new groups of drugs released on the market in the last period are being associated with much hope are gliptin — dipeptidyl peptidase- IV inhibitors (DPP-IV). Linagliptin is a new DPP-IV inhibitor. Authors demonstrated, that linagliptin assures meaning statistically and essential clinically effectiveness in all therapeutic outlines at present applied, so like of the monotherapy, supply with metformin, with metformin and sulphonylurea as well as initial association with pioglitazon. Improvement in the control of the blood glucose level as a result of the treatment linagliptin HbA_1c, FGP and PPG values, meaning beneficial changes and the improvement in parameters of functioning of beta cells observed. Risk of side effects, particularly a risk of the appearance of the hypoglycemia is similar like applying in placebo group. (Diabet. Prakt. 2011; 12, 5: 161–169)